AUG 17, 2026 · PHASE 3 TRIAL
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
ClinicalTrials.gov
This is a recruiting Phase 3 RCT with no posted results; the registry record describes study design and planned enrollment only, making it impossible to assess efficacy or safety.
Reported
Planned enrollment680
Study phasePhase 3
Primary outcome measureOverall Survival